1. Introduction {#sec1-animals-09-00501}
===============

Canine Leishmaniasis (CL) is a relevant endemic zoonotic disease in Mediterranean region where dogs are considered to be the main reservoirs hosts. In Europe, CL is caused by the protozoan *L. infantum* and usually transmitted by phlebotomine sand flies, although non-vectorial transmission is also reported \[[@B1-animals-09-00501],[@B2-animals-09-00501],[@B3-animals-09-00501]\]. Clinical symptomology and progression of CL is variable \[[@B4-animals-09-00501],[@B5-animals-09-00501]\]. CL can range from a self-limiting disease with sub-clinical appearance \[[@B6-animals-09-00501],[@B7-animals-09-00501]\], to a non-self-limiting infection with severe clinical features \[[@B4-animals-09-00501],[@B8-animals-09-00501],[@B9-animals-09-00501]\]. Subclinical or moderate infection is generally characterized by effective anti-*Leishmania* Th1 response with interferon (IFN)-γ and tumour necrosis factor (TNF)-α production that increases the leishmanicidal activity of the macrophages \[[@B10-animals-09-00501],[@B11-animals-09-00501],[@B12-animals-09-00501]\]. On the contrary, CL severe disease is associated with poor cell-mediated immune response and the occurrence of a mixed Th1 and Th2 cytokine profile \[[@B13-animals-09-00501]\]. Involvement of CD4^+^CD25^high^Foxp3^+^ T regulatory cells (Treg) could be of critical relevance during CL \[[@B14-animals-09-00501],[@B15-animals-09-00501],[@B16-animals-09-00501]\]. Treg regulate the recruitment and activation of immune effectors \[[@B17-animals-09-00501]\]. During CL, Treg activity may suppress anti-parasite immune response and exacerbate the *L. infantum* growth, favouring severe disease occurrence. On the contrary, Treg could avoid both the immune-mediated tissue damage and autoimmune processes in CL \[[@B18-animals-09-00501],[@B19-animals-09-00501],[@B20-animals-09-00501],[@B21-animals-09-00501],[@B22-animals-09-00501],[@B23-animals-09-00501],[@B24-animals-09-00501],[@B25-animals-09-00501]\]. In this regard, we previously described the occurrence of CD8^+^CD3^+^ T and Th1 cell increase accompanied by Treg decrease in CL \[[@B14-animals-09-00501]\].

Meglumine antimoniate, miltefosine and aminosidine are the only registered drugs for CL in Europe \[[@B22-animals-09-00501]\]. Administration of Allopurinol during and after antimonial treatment avoids relapses \[[@B22-animals-09-00501],[@B26-animals-09-00501]\]. Therapy with Allopurinol alone should be continued for 6 months \[[@B27-animals-09-00501]\] or one year \[[@B22-animals-09-00501],[@B28-animals-09-00501],[@B29-animals-09-00501]\]. The combination of miltefosine with Allopurinol and Amphotericin B represents the second and the third lines of CL therapy \[[@B22-animals-09-00501]\]. Efficacy of CL therapies varies from poor to good \[[@B22-animals-09-00501],[@B30-animals-09-00501],[@B31-animals-09-00501],[@B32-animals-09-00501]\]. Majority of CL dogs clinically ameliorated after one month of CL therapy \[[@B33-animals-09-00501]\], although a longer period is required to achieve complete clinical recovery. Reports of incremental resistance to antimonial drugs in CL \[[@B34-animals-09-00501]\] has induced the discovery of new drugs or natural origin compounds for the treatment of leishmaniasis in human and dogs \[[@B35-animals-09-00501]\]. Moreover, preventive vaccination and topical ectoparasiticidals against sand-flies have been suggested \[[@B22-animals-09-00501]\].

Unbalanced diet and hyponutrition are associated with increased susceptibility to infection \[[@B36-animals-09-00501],[@B37-animals-09-00501],[@B38-animals-09-00501],[@B39-animals-09-00501]\]. In addition, malnutrition was referred as a primary cause of immune suppression and could represent a major risk factor for the susceptibility to leishmaniosis in humans and animals \[[@B40-animals-09-00501],[@B41-animals-09-00501],[@B42-animals-09-00501],[@B43-animals-09-00501]\]. Since immune cell homeostasis and metabolism are stringently correlated, this interdependence could open to innovative immune-modulating therapeutic approaches for the treatment of infectious diseases \[[@B44-animals-09-00501],[@B45-animals-09-00501]\]. In this context, the use of plant-derived nutraceuticals may regulate immune responses \[[@B46-animals-09-00501]\] and improve the clinical outcome of infectious diseases in both human and dog models \[[@B47-animals-09-00501],[@B48-animals-09-00501],[@B49-animals-09-00501],[@B50-animals-09-00501]\]. Cortese et al. \[[@B15-animals-09-00501]\] reported that the combination of nutraceutical pet food with conventional therapy may modulate immune responses in CL. Nutraceutical diet administration correlated with the Th1 response decrease and Treg increase, and with the amelioration of CL clinical symptoms \[[@B15-animals-09-00501]\]. In addition, Segarra et al. \[[@B51-animals-09-00501]\] reported the efficacy (marked improvement in clinical and clinicopathological signs) of a treatment with dietary nucleotides and active hexose correlated compound in addition to N-methylglucamine antimoniate in dogs with leishmaniasis. Sesquiterpene (-)-α-bisabolol has been described to be effective in regulating Th1 response and in inducing clinical improvement in CL \[[@B52-animals-09-00501]\].

In the present study, we evaluated the efficacy of the administration of a commercial nutraceutical supplementation in dogs naturally affected by CL. This supplement is a combination of: Krill oil and flour, *Cordyceps sinensis* L., *Gentiana Lutea* L. and *Eleutherococcus senticosus* L., and is proposed to be added to the normal diet of dogs to support the natural physiological immune-response against chronic leishmaniasis. *Cordyceps sinensis* L. has been used as a tonic for longevity, endurance and vitality \[[@B53-animals-09-00501]\]. Such nutraceutical modulates immune responses \[[@B54-animals-09-00501],[@B55-animals-09-00501]\], inhibits tumour cell proliferation \[[@B56-animals-09-00501]\], enhances hepatic function \[[@B57-animals-09-00501]\], decreases plasma cholesterol levels \[[@B58-animals-09-00501]\] and exhibits hypotensive and vasorelaxant properties \[[@B59-animals-09-00501]\]. Krill oil, extracted from the Antarctic krill (*Euphausia superba*), has been described for its anti-oxidative effect, due to astaxanthin, which keeps intact the ω-3 polyunsaturated fatty acids (PUFA) and thereby protects them from oxidation \[[@B60-animals-09-00501]\]. Several studies suggest the health benefits of PUFA, in particular eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in terms of cardiovascular and anti-inflammatory effects \[[@B61-animals-09-00501],[@B62-animals-09-00501],[@B63-animals-09-00501]\]. *Gentiana lutea* is an ancient medicinal plant with its root (*Gentianae radix*) possessing the pro-drug. Phytochemically, it is characterized by the presence of active constituents, like secoiridoids, iridoids and xanthones. Recently, it has been found that this plant is a natural source of xanthone compounds that possess antioxidative, hypoglycemic, anti-viral, anti-bacterial and hepatoprotective activities \[[@B64-animals-09-00501],[@B65-animals-09-00501]\]. *Eleutherococcus senticosus* L. (Siberian ginseng) is an "adaptogen"---a stabilizer of several physiological process to increase homeostasis and stress resistance \[[@B66-animals-09-00501]\]. The synergy of various herbs allows to achieve a therapeutic activity \[[@B67-animals-09-00501]\].

In order to identify the potential immunomodulatory properties of the above nutraceutical supplement, we analysed the immune profile of 12 *L. infantum* naturally infected dogs (Nutraceutical Supplement group, NS-group), as compared with 20 sex/age-paired healthy dogs (Control group, CTR-group) at diagnosis and during a three-month follow-up.

2. Materials and Methods {#sec2-animals-09-00501}
========================

2.1. Ethical Statement {#sec2dot1-animals-09-00501}
----------------------

Dog owners provided formal consent to house the animals in adequate facilities, to treat their dogs with the nutritional supplement and to take samples. Ethical Animal Care and Use Committee approval was obtained (OPBA, CSV, University of Naples Federico II, prot. n. 2017/0069148). This research avoided discomfort to the animals by following animal welfare guidelines.

2.2. Composition of the Nutraceutical {#sec2dot2-animals-09-00501}
-------------------------------------

The commercial supplement is a combination of: Krill oil 3%, dry mushrooms (*Cordyceps sinensis* L.) 2%, Krill flour 1%, Gentian (*Gentiana Lutea* L.) dry root and products obtained from the extraction of herbs (*Eleutherococcus senticosus* L.).

2.3. Dog Enrolment and Study Design {#sec2dot3-animals-09-00501}
-----------------------------------

Twelve domesticated CL-positive dogs were enrolled in Campania region (South Italy) under the supervision of the veterinarians from the Department of Veterinary Medicine and Animal Productions of the University of Study Federico II (Naples, Italy). Criterion followed for the inclusion of the subjects in the study was (i) adult dogs in the homogenous age range of 5--7 years (to exclude age groups that might have too immature or too compromised immune systems) with laboratory confirmed positivity for leishmaniasis; (ii) clinical and pathological signs of CL; (iii) and indirect immunofluorescence antibody test (IFAT) titre ≥ 160; iv) positivity of *L. infantum* DNA in sternal bone marrow (BM) aspirate, assessed by nested polymerase chain reaction (n-PCR). The exclusion criteria followed was (i) pregnant or lactating dogs (as reported by owners and in some cases, confirmation done through abdominal ultrasonography); (ii) dogs suffering with hepatic or renal disease (haematological and biochemical analysis); (iii) dogs suffering with concomitant infective diseases (see [Section 2.7](#sec2dot7-animals-09-00501){ref-type="sec"}); and (iv) dogs treated against leishmaniasis in the last 2 years (as reported by owners). In addition, 20 healthy dogs (12 males, 8 females, equivalent in age to sick dogs) were included as control subjects (CTR-group). Healthy dogs were enrolled considering (i) clinical health condition (neither clinical signs of leishmaniasis or other infectious diseases); (ii) no clinical--pathological abnormalities by routine laboratory tests; (iii) IFAT negative (titre ≤ 1:40); (iv) negative n-PCR; and (v) exclusion of concomitant infectious diseases as described below (see [Section 2.7](#sec2dot7-animals-09-00501){ref-type="sec"}).

In the Nutraceutical Supplement group (NS-group), CL-positive dogs received no drug treatment for 4 weeks before commencement of the trial and were administered the nutraceutical at the dose rate of 0.5 g/kg body weight for 90 days, orally. Dogs were evaluated before treatment (T0), one month (T30) and 3 months (T90) after the nutraceutical treatment. Accurate clinical examination and the blood sampling for haematological, biochemical, serological and immunological analysis were performed at T0, T30 and T90.

The CTR-group was observed at T0 and provided both the normal control for the clinical parameters and the normality range for immune cells in our trial to be compared with NS-group.

*Leishmania* DNA n-PCR detection was performed on sternal BM aspirates in enrolled dogs at T0.

Nutraceutical supplementation was regularly added to pet food by the same dog owners before the diet administration. Diet satisfied the nutritional requirement of adult dogs in both CTR and NS groups. All dogs were subjected to ecto- and endoparacitidal treatment before the commencement of the study.

2.4. Clinical Evaluation of Dogs {#sec2dot4-animals-09-00501}
--------------------------------

Clinical assessment of leishmaniasis was done by veterinarians according to the criteria developed by da Silva et al. \[[@B68-animals-09-00501]\]:

Systemic signs---Attitude: active (0), apathetic (1); fever: absence (0), presence (1); lameness: absence (0), presence (1); nutritional status: normal (0), thin (1), cachectic (2); lymph nodes: normal (0), enlarged (1); mucosal colour: normal (0), pale (1); bleeding: absence (0), presence (1).

Cutaneous signs---Bristles: good (0), regular (1), bad/opaque (2); ear/nasal hyperkeratosis: absence (0), presence (1); nails: normal (0), long/onychogryphosis (1); skin lesion: absence (0), presence (1), ulcer (2); muzzle depigmentation: absence (0), presence (1); alopecia: absence (0), presence (1).

Ocular signs---Blepharitis: absence (0), presence (1); keratoconjunctivitis: absence (0), serous (1), mucopurulent (2).

All the individual scores were awarded to obtain a total sign-based score ranging between 0 and 19 (15 signs). Occurrence of other illnesses was monitored during the trial to rule out any positive dog. The clinical scores (CS) were obtained prior to treatments (T0) and at 1 (T30) and 3 months (T90).

2.5. Blood Sample Collection {#sec2dot5-animals-09-00501}
----------------------------

Ten millilitres of peripheral blood (PB) were collected by jugular venepuncture after 12 h of fasting. Total PB amount was divided into three fractions. Complete blood count (CBC) was performed within 30 min from the collection using semi-automatic cell counter (Genius S, SEAC Radim Florence, Italy). Thrombocytopenia or evidence of platelet clumping was evaluated by May--Grünwald--Giemsa-stained blood smears. Blood chemistry analyses was performed on serum aliquots by automatic biochemical analyser (AMS Autolab, Diamond Diagnostics, Holliston, MA, USA) using reagents from Spinreact (Girona, Spain) to determine: blood urea nitrogen (BUN), creatinine, aspartate amino transferase (AST), alanine-aminotransferase (ALT), gamma-glutamyltransferase (GGT), alkaline phosphatase (ALP), total cholesterol, triglycerides, albumin and total serum proteins (TP). Serum protein electrophoresis was also evaluated.

In addition, interferon-γ was assayed in serum using Elisa kits (Genorise, Philadelphia, PA, USA).

2.6. Serological and Molecular Assays {#sec2dot6-animals-09-00501}
-------------------------------------

Presence of anti-*Leishmania* antibodies was detected by indirect immunofluorescence antibody test (IFAT) using *L. infantum* promastigotes (WHO reference strain MHOM/TN/1980/IPT-1) as described \[[@B69-animals-09-00501]\]. The cut-off dilution was set at 1:160.

*E. canis* positivity was evaluated by IFAT using *E. canis* antigen in DH82 cells with a cut-off titre of 1:80.

The sternal bone marrow aspirate for *Leishmania* and *E. canis* DNA detection by n-PCR was performed as described \[[@B70-animals-09-00501],[@B71-animals-09-00501]\].

2.7. Diagnostic Procedure {#sec2dot7-animals-09-00501}
-------------------------

Diagnosis of CL in all dogs with clinical or clinical--pathological signs attributable to the infection was always confirmed by anti-*Leishmania* antibody titres (≥1:160) and positive molecular diagnosis. IFAT was evaluated three times (T0, T30 and T90) in NS-group.

Negative IFAT (≤1:80) and PCR, combined with the absence of clinical signs on physical examination, characterized the dogs to be included in the CTR group.

In CTR and NS-groups, dogs detected positive for *Ehrlichia canis*, *Anaplasma phagocytophilum morulae*, *Babesia canis* trophozoites and microfilariae in peripheral blood smears were excluded from the group. Ehrlichiosis was also evaluated as described above in [Section 2.6](#sec2dot6-animals-09-00501){ref-type="sec"}. *Dirofilaria immitis* infection was detected by Snap Canine Combo Heartworm Antigen Antibody Test (IDEXX).

2.8. Monoclonal Antibodies, Immunofluorescence, Flow Cytometry and Cell Culture {#sec2dot8-animals-09-00501}
-------------------------------------------------------------------------------

T cells and Treg cells were analysed by immune-fluorescence and flow cytometry (two-laser equipped FACScalibur apparatus and the CellQuest analysis software, (Becton Dickinson, Franklin Lakes, NJ, USA). Immune-fluorescence staining was performed by Fluorescin isothiocyanate (FITC), Phycoerythrin (PE), Cy-chrome and Allophycocyanin (APC) labelled monoclonal antibodies (mAbs) against dog CD3 (Clone CA17.2A12), CD4(Clone YKIX302.9), CD8 (Clone YCATE55.9), CD45 (clone CA12.10C12), IFN-γ (Clone CC302), IL-4 (Clone CC303) and isotype-matched controls (Serotec Ltd, London, UK). Intracellular Foxp3 was evaluated by a cross-reactive murine anti-FoxP3 mAb (Clone FJK-16 s, eBioscience, San Diego, CA, USA) and commercial detection Kit (FoxP3 Staining Set, eBioscience). Tregs were detected as per established protocols \[[@B14-animals-09-00501],[@B15-animals-09-00501],[@B72-animals-09-00501]\]. Peripheral blood mononuclear cells (PBMC) were purified with density gradient, cultured in RPMI 1640 (Biochrom GmbH Berlin, Germany), supplemented with 5% heat inactivated foetal bovine serum and 2 mM glutamine (Biochrom) at 37 °C in 5% CO2/95% air and incubated overnight with Phorbol myristate acetate (PMA) and Ionomycin (Sigma-Aldrich, St. Louis, MO, USA), in the presence of 5 μg/ml of Brefeldin-A (Sigma-Aldrich, St. Louis, MO, USA), to analyse IFN-γ production \[[@B14-animals-09-00501],[@B15-animals-09-00501],[@B73-animals-09-00501],[@B74-animals-09-00501]\]. IFN-γ intracellular staining was obtained using a fixation/permeabilization kit (eBioscience). Forward Scatter (FSC) and Side Scatter (SSC) parameter strategy was applied to all analysed samples \[[@B14-animals-09-00501],[@B15-animals-09-00501]\].

2.9. Statistical Analysis {#sec2dot9-animals-09-00501}
-------------------------

Blood count, blood biochemistry and inflammatory parameters were compared by General Linear Model as: where: y is the dependent variable, μ is the mean, G is the group effect (i = NS, CTR), T is the time effect (j = 0, 30, 60, 90), G × T is the first level of interaction and ε is the error effect.

When significant differences were found in the ANOVA, means were compared using Tukey's test.

Clinical signs were analysed by non-parametric Wilcoxon signed-rank test. All the statistical procedures were performed used JMP software version n. 9 (SAS Institute, Cary, NC, USA). Immunological parameters were evaluated by Wilcoxon matched pairs test (Graph-Pad Prism Inc, San Diego, CA, USA).

3. Results {#sec3-animals-09-00501}
==========

3.1. Clinical and Laboratory Evaluation {#sec3dot1-animals-09-00501}
---------------------------------------

All the enrolled sick dogs were symptomatic. A progressive improvement in the clinical response was observed in NS-group during the 3 months of follow-up period. No mortality was observed in the CTR and NS-group during the study. Clinical recovery was considered when a reduction in the clinical score was observed during the study. Before treatment with the nutraceutical supplement (T0), the mean clinical score in infected dogs was 6.0 (range 2--9), while the enrolled dogs showed an overall and progressive clinical improvement during follow-up (T30 mean score: 4.8, range: 1--8; T90 mean score: 3.1, range: 1--6) ([Table 1](#animals-09-00501-t001){ref-type="table"}). Notably, IFAT titres showed a progressive reduction ([Table 1](#animals-09-00501-t001){ref-type="table"}).

All haematological and biochemical parameters were within the normal range for adult dogs and no signs of adverse effects were observed after clinical examination, demonstrating that supplementation was well tolerated. Haematocrit (HT), mean corpuscular volume (MCV) and mean corpuscular haemoglobin (MCH) decreased significantly (*p* \< 0.01) while mean corpuscular haemoglobin concentration (MCHC) increased significantly (*p* \< 0.01) in NS-group after 90 days of treatment. White blood cells (WBC) also decreased significantly (*p* \< 0.05) at day 90. Aspartate amino transferase (AST) and Blood Urea Nitrogen (BUN) resulted significantly (*p* \< 0.01) higher at day 90 whereas Gamma Glutamyl Transferase (GGT) significantly increased at day 30 but decreased at day 90 compared to day 0. Beta2 and gamma globulins significantly decreased at both 30 and 90 days (*p* \< 0.05 and *p* \< 0.01, respectively). Interferon-γ decreased at both 30 and 90 days (*p* \< 0.05) in NS-group compared to CTR-group.

3.2. Immune Phenotype Analysis {#sec3dot2-animals-09-00501}
------------------------------

We analysed by Flow Cytometry the CD8 T lymphocyte percentage in NS-Group. We observed a moderate but significant decrease of CD8 T lymphocyte percentage between NS-Group and CTR-Group at T0 (*p* = 0.02) and T30 (*p* = 0.01) ([Figure 1](#animals-09-00501-f001){ref-type="fig"}). CD8 T lymphocyte percentage appeared to be slightly recovered at T90 when compared to T0 and T30 and became similar to the level expressed in CTR dogs. This occurrence suggests that nutraceutical supplementation was able to normalize CD8 T cell level in NS-Group. In contrast, CD4 T lymphocyte percentage unchanged in NS-Group upon nutraceutical supplementation ([Figure 2](#animals-09-00501-f002){ref-type="fig"}B). Notably, the moderate decrease of CD8 T lymphocyte percentage and the unchanged CD4 T lymphocyte percentage could explain why the CD4:CD8 T cell ratio remained substantially unmodified in NS-Group at T30 and T90 ([Figure 2](#animals-09-00501-f002){ref-type="fig"}A). It is noteworthy that, although the differences are not significant, the CD4--CD8 ratio appeared to be increased at T0 and T30 when compared to the CTR-Group, while it seemed to be normalized at T90 and similar to the CD4--CD8 ratio expressed in the CTR-Group. Treg percentage in the NS-Group and CTR-Group revealed a significant reduction at T0 (*p* = 0.01) and T30 (*p* = 0.01) ([Figure 3](#animals-09-00501-f003){ref-type="fig"}A). Treg percentage restored only at T90 in NS-Group dogs and became similar to CTR-Group ([Figure 3](#animals-09-00501-f003){ref-type="fig"}A). This result strongly suggests that Treg restoration could be correlated to the nutraceutical supplement administration.

We evaluated whether nutraceutical supplement administration could modify the Th1 activity in CL dogs. Th1 cell percentage increased in NS-Group at T0 compared with CTR-Group dogs (*p* = 0.03) ([Figure 3](#animals-09-00501-f003){ref-type="fig"}B). This result is in accordance with our previous study on CL \[[@B14-animals-09-00501]\]. Nutraceutical supplementation administration appears to be associated with Th1 cell decrease at T30 (*p* \< 0.0001) and T90 (*p* = 0.01) in NS-Group. This evidence was also confirmed by ELISA approach in serum CL dogs, since the IFN-γ detection changed from T0 (260.32 pg/mL) to T30 (196.25 pg/mL) and T90 (157.06 pg/mL) in NS-Group.

4. Discussion {#sec4-animals-09-00501}
=============

Here, we described a significant improvement in clinical conditions in CL dogs treated with a nutraceutical supplement. Moreover, IFAT titres showed a progressive reduction during the follow up even if the use of antibody levels to assess clinical improvement is controversial \[[@B75-animals-09-00501],[@B76-animals-09-00501],[@B77-animals-09-00501]\].

No signs of adverse effects were observed after clinical examination, showing that supplementation was well tolerated. Notably, some significant differences in biochemical parameters were detected. In particular, AST was higher in NS-group than in CTR after 30 (35.8 + 8.0 U/L) and 90 (46.8 + 6.6 U/L) days of treatment vs. day 0 (37.1 + 8.2 U/L), but its levels were still comprised within physiological range. Moreover, in case of liver damage, increases in AST parallel those in ALT, which is considered a much more liver-specific marker \[[@B78-animals-09-00501]\], but ALT did not change after the supplement administration, thus excluding even a liver overload.

Likewise, BUN was higher in the NS group than in CTR at days 30 (35.5 + 4.4 U/L) and 90 (40.0 + 10.1 U/L) compared to day 0 (29, 7 + 7.6 U/L), also in this case in the physiological range. During leishmaniasis the kidney is primarily damaged \[[@B79-animals-09-00501]\]. Thus, the BUN dosage can provide useful information on the status of the kidneys. However, its prognostic value is closely related to creatinine levels \[[@B80-animals-09-00501]\], which were not influenced in the NS group. Therefore, the detected increases of AST and BUN have a limited diagnostic value in the NS-group dogs. In light of the clinical, biochemical and serological results, our study highlighted an improvement in the condition of CL dogs after 3 months of treatment with oral nutraceutical supplementation (NS group).

Ingredients present in the nutraceutical supplement were described to exert anti-oxidative and anti-inflammatory effects, cardiovascular benefits, hypoglycemic, anti-viral, anti-bacterial and hepatoprotective responses. *C. sinensis* L. activates murine macrophages responsible of the production of a variety of pro-inflammatory cytokines and IFN-γ synergizes with such nutraceutical in order to amplify this response \[[@B81-animals-09-00501]\]. *C. sinensis* reduces the incidence of diabetes, which is due to an increase in the portion of Treg cells/Th17 in the spleen and pancreatic lymph nodes \[[@B82-animals-09-00501]\]. Non-obese diabetic (NOD) mice treated with *C. sinensis* extract showed slowed disease development. However, in peripheral lymph nodes, treatment with *C. sinensis* extract increases the frequency of IFN-γ and Treg cells producing Th1 cells. Moreover, Chen et al. \[[@B83-animals-09-00501]\] showed significantly reduced CD4^+^ T cells and increased percentages of CD8^+^ T cells in peripheral blood mononuclear cells (PBMC) after *C. sinensis* administration in mice affected by lupus-prone autoimmune.

Based on in vitro data, the anti-inflammatory activity arising from *Gentiana lutea* L. is represented by the ability to inhibit myeloperoxidase enzymes, which are released during degranulation of neutrophils and monocytes. Myeloperoxidase upregulation is known to contribute to the development of inflammatory and immune-mediated complications \[[@B84-animals-09-00501]\].

Treg cells have been found to play a critical role to maintain self-tolerance and to prevent autoimmune diseases. Moreover, after nutraceutical administration we observed a slight restoration of Treg cells, whose low level has been associated with chronic CL \[[@B14-animals-09-00501],[@B15-animals-09-00501]\]. Indeed, Treg levels appear to be increased upon treatment and become similar to those of control dogs after 90 days (T90) of nutraceutical administration. Notably, IFN-γ production progressively decreased in NS-group dogs.

Nutraceutical supplementation seems to specifically act on Treg and Th1 lymphocytes, since other type of T cells appear to be unaffected or only moderately decreased. In this regard, the unaltered T cell effector activity could ensure immune response against the parasite, while Treg increase and the modulation of Th1 inflammatory response could preserve tissues from the immune-mediated damages occurring in CL \[[@B15-animals-09-00501],[@B18-animals-09-00501],[@B19-animals-09-00501],[@B21-animals-09-00501],[@B22-animals-09-00501],[@B23-animals-09-00501],[@B24-animals-09-00501],[@B25-animals-09-00501]\]. Moreover, the nutraceutical-induced immuno-modulation could also improve the overall clinical conditions of sick dogs due to the reduction of the inflammatory context in the pathophysiology associated with CL, such as immune-mediated thrombocytopenia \[[@B14-animals-09-00501]\]. Taken in all, our results showed that this peculiar nutraceutical supplement could modulate Th1 immune response and significantly improve clinical amelioration of the infected animals.

5. Conclusions {#sec5-animals-09-00501}
==============

Nutraceuticals as a dietary supplement appear to be of tangible benefit in the clinical management of dogs affected with chronic CL. In fact, the clinical improvement and a beneficial modulation of the immune response are observed in this clinical trial. In particular, the reduction of potential adverse inflammatory events, mediated by the exacerbated INF-γ secretion and Treg percentage decreasing usually observed in CL \[[@B15-animals-09-00501],[@B18-animals-09-00501],[@B19-animals-09-00501],[@B21-animals-09-00501],[@B22-animals-09-00501],[@B23-animals-09-00501],[@B24-animals-09-00501],[@B25-animals-09-00501]\], may be limited by the use of those nutraceuticals able to reduce the pro-inflammatory cytokine production and to increase Treg percentage. Nutraceutical supplementation appears that are able to improve the immune-modulatory response in the clinical recovery of CL dogs, independently of the conventional anti-CL treatment. The present study does not point to the replacement of CL with this nutraceutical supplementation, but suggests its use as an adjunct therapy to the conventional medical treatment of chronic canine leishmaniasis. In this regard, this study highlighted that nutraceutical supplement administration is associated with Th1 immune response modulation and significant clinical improvement of the infected animals.

6. Limitations {#sec6-animals-09-00501}
==============

This study has some limitations: (1) No evaluation was performed to establish which ingredient is the most active in the complex of employed supplementation; (2) Absence of control group of dogs treated with other anti-oxidant and other extracts of plants, different from those here employed; (3) Absence of control group of dogs treated with conventional anti-leishmanial therapy; (4) No blinded study was conducted; (5) The trial has been performed only in 90 days-follow-up; (6) The limited sample size (12 dogs).
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![CD8 T lymphocyte percentage in NS-Group. Significant decrease of CD8 T lymphocyte percentage between NS-Group and CTR-Group was observed at T0 (*p* = 0.02) and T30 (*p* = 0.01). CD8 T lymphocyte percentage appeared to be recovered at T90 when compared to T0 and T30 and similar to the level expressed in healthy dogs. Referred values indicate results obtained in CTR-Group (dashed column), in NS-Group dogs at T0 (white column), T30 (grey column), and T90 (black column), as indicated. Wilcoxon matched-pairs signed-rank test was used for the statistical analysis NS means not significant difference.](animals-09-00501-g001){#animals-09-00501-f001}

![CD4 T lymphocyte percentage and CD4:CD8 cell ratio in NS-Group. CD8 T lymphocyte percentage, CD4--CD8 T cell ratio (**A**) and CD4 T lymphocyte percentage (**B**) appeared unmodified in NS-Group at T30 and T90. Referred values indicate results obtained in CTR-Group (dashed column), in NS-Group dogs at T0 (white column), T30 (grey column) and T90 (black column). Wilcoxon matched-pairs signed-rank test was used for the statistical analysis. NS means not significant difference.](animals-09-00501-g002){#animals-09-00501-f002}

![Treg lymphocyte percentage and IFN-γ producing CD3 T Lymphocytes in NS-Group. (**A**) shows the percentage reduction of Treg cells of sick dogs was observed at T0 (*p* = 0.01) and T30 (*p* = 0.01). Recovery of Treg was observed only at T90 in NS-Group. (**B**) NS-Group showed an increase of IFN-γ producing CD3 T Lymphocyte percentage at T0 as compared with CTR-Group. Nutraceutical supplementation appeared to decrease IFN-γ production at T30 and T90 in NS-Group. Referred values indicate results obtained in CTR-Group (dashed column), in NS-Group dogs at T0 (white column), T30 (grey column), and T90 (black column). Wilcoxon matched-pairs signed-rank test was used for the statistical analysis. NS means not significant difference.](animals-09-00501-g003){#animals-09-00501-f003}
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###### 

Evolution of clinical score (CS) and immunofluorescence antibody test (IFAT) titres in dogs belonging to NS group at time 0 (T0) and after 1 (T30) and 3 months (T90) of nutraceutical supplementation.

  NS Group Dogs   T0       T30      T90
  --------------- -------- -------- --------
  **1** CS        3        1        1
  IFAT            1:1280   1:1280   1:320
  **2** CS        9        8        6
  IFAT            1:640    1:640    1:80
  **3** CS        7        6        2
  IFAT            1:640    1:640    1:320
  **4** CS        7        6        5
  IFAT            1:1280   1:640    1:160
  **5** CS        6        6        4
  IFAT            1:640    1:320    1:160
  **6** CS        7        6        4
  IFAT            1:320    1:320    1:40
  **7** CS        5        5        3
  IFAT            1:1280   1:640    1:1280
  **8** CS        9        6        2
  IFAT            1:640    1:640    1:320
  **9** CS        7        3        3
  IFAT            1:320    1:160    1:320
  **10** CS       6        3        3
  IFAT            1:320    1:160    1:160
  **11** CS       5        2        2
  IFAT            1:160    1:160    1:80
  **12** CS       3        3        2
  IFAT            1:640    1:640    1:160

[^1]: These authors contributed equally to this work.
